To include your compound in the COVID-19 Resource Center, submit it here.

Par Pharmaceutical infectious, cancer, endocrine news

Par will restructure and reduce headcount by about 100 in its Strativa Pharmaceuticals unit. The company said most of the

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE